Want to join the conversation?
$VRTX has exclusively licensed VX-210 to treat acute spinal cord injury from BioAxone BioSciences. VX-210 is designed to inhibit protein known as Rho that blocks neural regeneration after injury. $VRTX will start Phase 2b/3 clinical trial in 1H16 to evaluate efficacy and safety of VX-210 in patients with certain acute cervical spinal cord injuries.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.